[Consequences of Gout and Hyperuricemia]

Area of Science:

• Cardiovascular Science
• Nephrology
• Neurology

Background:

• Hyperuricemia (HU) and gout exhibit strong associations with cardiovascular disease (CVD), likely stemming from shared underlying etiologies.
• HU is causally linked to metabolic syndrome, obesity, and can contribute to or result from impaired kidney function.
• Observational studies suggest potential protective effects of HU against neurodegenerative conditions like Alzheimer's and Parkinson's disease.

Purpose of the Study:

• To explore the complex relationship between hyperuricemia, gout, and associated comorbidities.
• To discuss the role of urate-lowering therapy (ULT) in managing gout and its impact on related health issues.
• To address existing controversies regarding HU's influence on cardiovascular and neurodegenerative diseases.

Main Methods:

• Review of existing literature on hyperuricemia, gout, and their associations with cardiovascular and neurodegenerative diseases.
• Analysis of observational data and ongoing randomized controlled trials (RCTs) concerning urate and ULT.
• Discussion of the etiological links between HU, metabolic syndrome, obesity, and kidney function.

Main Results:

• The association between HU/gout and CVD is likely multifactorial, involving shared risk factors rather than direct causality.
• HU and gout can negatively impact kidney function, while also being influenced by renal health.
• Emerging evidence suggests a potential neuroprotective role for HU in certain neurodegenerative diseases, though further research is needed.
• Ongoing RCTs are crucial for clarifying the causal relationships and therapeutic potential of ULT.

Conclusions:

• Gout is a curable condition with urate-lowering therapy (ULT).
• Adequate ULT may offer benefits for comorbidities associated with gout and hyperuricemia.
• Further research, including RCTs, is essential to fully understand the multifaceted roles of urate in health and disease.